MEI Pharma Inc (MEIP)
3.00
-0.03
(-0.99%)
USD |
NASDAQ |
Nov 14, 16:00
3.00
0.00 (0.00%)
After-Hours: 20:00
MEI Pharma Research and Development Expense (Quarterly): 3.944M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 3.944M |
| March 31, 2024 | 5.22M |
| December 31, 2023 | 3.912M |
| September 30, 2023 | 3.485M |
| June 30, 2023 | 2.57M |
| March 31, 2023 | 15.10M |
| December 31, 2022 | 15.31M |
| September 30, 2022 | 19.46M |
| June 30, 2022 | 21.84M |
| March 31, 2022 | 22.32M |
| December 31, 2021 | 21.53M |
| September 30, 2021 | 19.95M |
| June 30, 2021 | 16.29M |
| March 31, 2021 | 17.88M |
| December 31, 2020 | 22.22M |
| September 30, 2020 | 13.00M |
| June 30, 2020 | 7.859M |
| March 31, 2020 | 8.963M |
| December 31, 2019 | 8.281M |
| September 30, 2019 | 8.962M |
| June 30, 2019 | 8.032M |
| March 31, 2019 | 9.071M |
| December 31, 2018 | 9.066M |
| September 30, 2018 | 6.131M |
| June 30, 2018 | 4.459M |
| Date | Value |
|---|---|
| March 31, 2018 | 3.071M |
| December 31, 2017 | 3.444M |
| September 30, 2017 | 6.064M |
| June 30, 2017 | 2.073M |
| March 31, 2017 | 1.876M |
| December 31, 2016 | 1.642M |
| September 30, 2016 | 1.646M |
| June 30, 2016 | 3.985M |
| March 31, 2016 | 3.42M |
| December 31, 2015 | 3.182M |
| September 30, 2015 | 2.816M |
| June 30, 2015 | 3.779M |
| March 31, 2015 | 6.775M |
| December 31, 2014 | 6.703M |
| September 30, 2014 | 6.566M |
| June 30, 2014 | 6.413M |
| March 31, 2014 | 5.415M |
| December 31, 2013 | 4.40M |
| September 30, 2013 | 3.102M |
| June 30, 2013 | 1.651M |
| March 31, 2013 | 1.543M |
| December 31, 2012 | 1.338M |
| September 30, 2012 | 1.552M |
| June 30, 2012 | 1.32M |
| March 31, 2012 | 1.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.57M
Minimum
Jun 2023
22.32M
Maximum
Mar 2022
13.11M
Average
15.10M
Median
Mar 2023
Research and Development Expense (Quarterly) Benchmarks
| Avid Bioservices Inc | -- |
| Evoke Pharma Inc | 0.0117M |
| Revance Therapeutics Inc | 11.38M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 4.672M |